Stock Track | CRISPR Therapeutics Soars 5.03% as Partner Intellia Doses First Patient in Key Gene Editing Study

Stock Track03:20

CRISPR Therapeutics AG (NASDAQ: CRSP) saw its shares surge 5.03% in Wednesday's trading session amidst positive development for its partner company Intellia Therapeutics. The rally came as Intellia announced the dosing of the first patient in a pivotal Phase 3 study evaluating its investigational CRISPR gene editing therapy NTLA-2002 for the treatment of hereditary angioedema (HAE).

NTLA-2002, being developed in collaboration with CRISPR Therapeutics, has the potential to become the first one-time treatment for HAE, a rare and potentially life-threatening genetic disease. The Phase 3 study, called HAELO, aims to evaluate the efficacy and safety of a single infusion of NTLA-2002 in reducing the frequency of HAE attacks in patients.

The dosing of the first patient in this critical late-stage study marks a significant milestone for Intellia and CRISPR Therapeutics, bringing them one step closer to potentially revolutionizing the treatment paradigm for HAE patients. If successful, NTLA-2002 could offer patients independence from both HAE attacks and the need for chronic prophylactic medications currently used to manage the condition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135790457?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135790457","market":"us","top_or_hot":-1,"title":"Stock Track | CRISPR Therapeutics Soars 5.03% as Partner Intellia Doses First Patient in Key Gene Editing Study","media":"Stock Track","content":"<p>CRISPR Therapeutics AG (NASDAQ: CRSP) saw its shares surge 5.03% in Wednesday's trading session amidst positive development for its partner company Intellia Therapeutics. The rally came as Intellia announced the dosing of the first patient in a pivotal Phase 3 study evaluating its investigational CRISPR gene editing therapy NTLA-2002 for the treatment of hereditary angioedema (HAE).</p>\n\n<p>NTLA-2002, being developed in collaboration with CRISPR Therapeutics, has the potential to become the first one-time treatment for HAE, a rare and potentially life-threatening genetic disease. The Phase 3 study, called HAELO, aims to evaluate the efficacy and safety of a single infusion of NTLA-2002 in reducing the frequency of HAE attacks in patients.</p>\n\n<p>The dosing of the first patient in this critical late-stage study marks a significant milestone for Intellia and CRISPR Therapeutics, bringing them one step closer to potentially revolutionizing the treatment paradigm for HAE patients. If successful, NTLA-2002 could offer patients independence from both HAE attacks and the need for chronic prophylactic medications currently used to manage the condition.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CRISPR Therapeutics Soars 5.03% as Partner Intellia Doses First Patient in Key Gene Editing Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CRISPR Therapeutics Soars 5.03% as Partner Intellia Doses First Patient in Key Gene Editing Study\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-23 03:20 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CRISPR Therapeutics AG (NASDAQ: CRSP) saw its shares surge 5.03% in Wednesday's trading session amidst positive development for its partner company Intellia Therapeutics. The rally came as Intellia ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1135790457","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135790457","pubTimestamp":1737573639,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CRISPR Therapeutics AG  saw its shares surge 5.03% in Wednesday's trading session amidst positive development for its partner company Intellia Therapeutics. The rally came as Intellia announced the dosing of the first patient in a pivotal Phase 3 study evaluating its investigational CRISPR gene editing therapy NTLA-2002 for the treatment of hereditary angioedema .NTLA-2002, being developed in collaboration with CRISPR Therapeutics, has the potential to become the first one-time treatment for HAE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"随着合作伙伴Intellia在关键基因编辑研究中为首例患者注射药物，CRISPR Therapeutics股价飙升5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1},"content_text":"CRISPR Therapeutics AG (NASDAQ: CRSP) saw its shares surge 5.03% in Wednesday's trading session amidst positive development for its partner company Intellia Therapeutics. The rally came as Intellia announced the dosing of the first patient in a pivotal Phase 3 study evaluating its investigational CRISPR gene editing therapy NTLA-2002 for the treatment of hereditary angioedema (HAE).\nNTLA-2002, being developed in collaboration with CRISPR Therapeutics, has the potential to become the first one-time treatment for HAE, a rare and potentially life-threatening genetic disease. The Phase 3 study, called HAELO, aims to evaluate the efficacy and safety of a single infusion of NTLA-2002 in reducing the frequency of HAE attacks in patients.\nThe dosing of the first patient in this critical late-stage study marks a significant milestone for Intellia and CRISPR Therapeutics, bringing them one step closer to potentially revolutionizing the treatment paradigm for HAE patients. If successful, NTLA-2002 could offer patients independence from both HAE attacks and the need for chronic prophylactic medications currently used to manage the condition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135790457"}